Shoulder Innovations (SI) Q1 2026 earnings review
Blistering Top-Line Growth Masked by Widening Operating Losses
Shoulder Innovations delivered spectacular top-line execution in Q1, with revenue surging 65% YoY to $16.7M. The growth engine is firing on both cylinders: selling 51% more implants while commanding a 9% higher average selling price. However, the cost of this growth remains steep. Operating losses doubled to $9.0M as the company spends aggressively on commercial expansion and a new robotic platform. Management raised full-year guidance, but the implied sequential growth for the rest of the year looks suspiciously conservative.
🐂 Bull Case
Achieving 51% volume growth alongside a 9% increase in average selling price ($7,650) is the gold standard for medical device growth. Pricing power is rare in this market.
Management confidently raised FY26 revenue guidance to $65-$68M, signaling strong visibility and early traction from the new InSet I-135RFX Humeral Stem launch.
🐻 Bear Case
Despite a massive 65% jump in revenue and elite 77.7% gross margins, the company's operating loss worsened from $4.3M to $9.0M as expenses grew even faster than sales.
SG&A grew 73% and R&D exploded by 137%. The company is burning through cash to fuel its top-line momentum, widening Adjusted EBITDA losses to $7.0M.
⚖️ Verdict: ⚪
Neutral. The commercial traction and product adoption are undeniably bullish, but the aggressive cash burn and deteriorating operating margins demand caution. The company has the balance sheet to fund this phase, but investors need to see a path to leverage soon.
Key Themes
Implant Volume Acceleration
Volume growth is accelerating rapidly. The company sold 2,184 implant systems in Q1, up 51% YoY. This marks the fourth consecutive quarter of sequential volume increases, proving that their 'ecosystem' approach is winning genuine market share from legacy orthopedics players.
Pricing Power Materializing
Average selling price (ASP) rose 9% to $7,650. In a medical device landscape where hospitals fiercely push back on pricing, a 9% bump indicates high surgeon preference and a favorable product mix, likely driven by newer, premium-priced implants.
InSet I-135RFX Full Commercial Launch
The company moved from limited user release to full commercial launch for the InSet I-135RFX Humeral Stem, adding fracture indications to their portfolio. This expands their Total Addressable Market and provides a new catalyst for sales reps in FY26.
Expenses Far Outpacing Revenue
A concerning trend is solidifying: SG&A has grown faster than revenue. SG&A hit $18.2M (+73% YoY) compared to revenue of $16.7M (+65% YoY). The commercial organization expansion is working, but it is highly inefficient at this stage. Management must eventually demonstrate that a dollar of new sales costs less than a dollar to acquire.
R&D Cost Spike from Robotics
R&D expenses reversed their stable trend, spiking 137% to $3.8M. Management attributed this to a milestone payment and development costs for their new robotic platform strategic partnership. While robotics is necessary to compete with giants like Stryker, investors need clarity on whether this $3.8M is a new structural run-rate or a one-time blip.
Robust Balance Sheet Runway
Thanks to their Q3 2025 IPO and convertible note raises, the company sits on $108.5M in cash and marketable securities. Even with a quarterly cash burn tracking around $10M-$15M, they have a comfortable multi-year runway before needing to access dilutive capital markets again.
Other KPIs
Stable and excellent. Improved slightly from 76.9% in Q1 2025. This proves that the underlying unit economics of the business are highly profitable; the net losses are purely a function of scale and operating expense investments.
Reversing. Losses deepened from -$3.5M a year ago. While revenue grew by $6.6M YoY, the combination of SG&A and R&D grew by $9.9M over the same period, dragging Adjusted EBITDA down.
The massive optical improvement from -$52.13 a year ago is entirely an artifact of share dilution. The share count exploded from ~89k to over 20.6 million following the company's IPO and capital restructuring in the second half of 2025.
Guidance
Accelerating vs prior guidance, but implies a strange deceleration going forward. The midpoint ($66.5M) represents ~40% YoY growth. However, because Q1 already delivered $16.7M, the midpoint implies average revenue of just $16.6M for the remaining three quarters. This means management is either baking in massive seasonal headwinds or severely lowballing the rest of the year.
Key Questions
Guidance Conservatism
With Q1 revenue hitting $16.7M, your raised FY26 midpoint of $66.5M implies zero sequential growth for the remainder of the year. Are you expecting specific seasonal headwinds, or is this simply a conservative baseline?
Path to Operating Leverage
SG&A grew 73% this quarter compared to 65% revenue growth. At what annualized revenue scale do you expect the commercial organization investments to normalize, allowing operating margins to finally inflect positively?
R&D Run Rate
How much of the $3.8M in Q1 R&D expense was a one-time milestone payment for the Interventional Systems partnership, and what should we model as a normalized quarterly R&D run rate for the rest of FY26?